Amgen Presents New Tarlatamab Data In Small Cell Lung Cancer
Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC
Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Pharmaceuticals | Small Cell Lung Cancer